StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen stock-based compensation ($M) ($M)

Form 10-Q / 10-K (DB)

QuarterlyAnnual
Latest, Q2 2026
165
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
157 in Q2 2025
History
48 quarters
Since Q3 2008
Sources
40
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStock-based compensation ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026165+5.1%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 202675-11.8%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025125-6.7%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025127-6.6%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 20251570.0%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 202585-17.5%Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 2024134-16.8%Form 10-K (filed 2025-02-14) ↗
Q3 2024Sep 30, 2024136+30.8%Form 10-Q (filed 2024-10-31) ↗
Q2 2024Jun 30, 2024157+31.9%Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 2024103+119.1%Form 10-Q (filed 2024-05-03) ↗
Q4 2023Dec 31, 2023161–Form 10-Q (filed 2024-10-31) ↗
Q3 2023Sep 30, 2023104–Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023119–Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 202347–Form 10-Q (filed 2024-05-03) ↗
Q4 2018Dec 31, 201887+2.4%Form 10-K (filed 2019-02-13) ↗
Q3 2018Sep 30, 201877-12.5%Form 10-Q (filed 2018-10-31) ↗

Cite this data

StockData. (2026). Amgen Stock-based compensation ($M) ($M), quarterly Q3 2008–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_sbc

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.